01.07.25 -- Navigating The Challenges Of Bringing Cell And Gene Therapies To Market

Cell and gene therapies are witnessing rapid advancements, but significant challenges remain for their commercialization due to regulatory hurdles, manufacturing barriers, high costs, and safety concerns.

Stirred-tank bioreactors have emerged in recent years as the optimal platform to optimize (stem) cell culturing raising their potential in the cell and gene therapy industry.

Demands for flexible, scalable, cost effective manufacturing are prompting cell and gene therapy manufacturers and CDMOs to implement single-use technology for manufacturing their therapies.

Reach new heights in mAb production with a high-intensity perfusion CHO medium designed to support consistently high product yield and quality in continuous perfusion cultures using CHO-K1 cells.

Gain insight into how digital standardized tools can streamline your scaling processes and enable more accurate prediction and visualization of your scaling needs.

This study demonstrates the automated magnetic isolation of CD4/CD8+ cells from fresh or frozen leukapheresis using a functionally closed cell processing system paired with a modular application.

Explore the application of macro mass photometry in analyzing AdV vectors, distinguishing between empty and full viral capsids, and accurately measuring the proportion of full capsids present.

Explore a protocol for comparing the performance of Applied Biosystems PowerTrack SYBR Green Master Mix with other master mixes in PCR applications.

When it comes to fill-finish manufacturing of parenteral liquid pharmaceuticals, your choice of barrier technology is crucial.

Allogeneic Natural Killer (NK) cell therapy offers a promising avenue for cancer immunotherapy. However, traditional platforms struggle to achieve the scalability required for clinical translation and commercial manufacturing.